Agenus Inc. (AGEN)
NASDAQ:AGEN
Want to see AGEN full AI Analyst Report?
AGEN Stock Chart & Stats
$4.79
-$0.06(-1.69%)
At close: 4:00 PM EST
$4.79
-$0.06(-1.69%)
Day’s Range― - ―
52-Week Range$2.71 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)696.71K
Market Cap
$124.93M
Enterprise Value$392.73M
Total Cash (Recent Filing)$35.00M
Total Debt (Recent Filing)$304.46M
Price to Earnings (P/E)1.8
Beta2.55
Next Earnings
Aug 11, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.73
Shares Outstanding41,642,430
10 Day Avg. Volume665,681
30 Day Avg. Volume696,712
Financial Highlights & Ratios
PEG Ratio-8.12
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market Cap3.14
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit6.08
Enterprise Value/Ebitda3.09
Forecast
1Y Price Target
$23.00Price Target Upside380.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.3
Revenue Forecast (FY)$232.90M
Bulls Say, Bears Say
Bulls Say
Improving Profitability & RevenueTrailing-twelve-month results show a clear operational inflection: positive EBIT and a large swing to net income alongside rising revenue. This improvement, if sustained, reduces near-term funding pressure, supports ongoing R&D investment, and strengthens the firm's ability to advance its pipeline.
Collaboration-anchored Revenue ModelA business model built on collaborations, upfronts, R&D funding, milestones and potential royalties provides diversified non-product revenue streams. These deal-driven inflows can finance clinical programs, share development risk with partners, and provide recurring funding opportunities as programs advance.
Legal Overhang RemovedThe dismissal of the securities class action removes a major litigation overhang and associated uncertainty. That structural reduction in legal risk improves predictability for planning, reduces potential future liabilities, and makes it easier to focus management and capital on R&D and partnership execution.
Bears Say
Negative Equity & LeveragePersistent negative stockholders' equity and material leverage curtail financial flexibility. This capital-structure weakness increases refinancing and dilution risk, limits ability to absorb setbacks, and constrains strategic optionality for M&A or large-scale program funding over the medium term.
Sustained Cash BurnMulti-year negative operating and free cash flow imply ongoing reliance on external capital to fund operations and trials. That structural cash-burn profile elevates financing risk, increases likely shareholder dilution, and can limit consistent investment pacing across the pipeline if capital markets tighten.
Accounting Leadership TurnoverLoss of the principal accounting officer creates near-term operational and reporting risk: transitions can disrupt financial controls, delay reporting, and complicate capital-raising or covenant discussions. Recruiting and onboarding may distract management and affect financial continuity over the next several months.
Agenus News
AGEN FAQ
What was Agenus Inc.’s price range in the past 12 months?
Agenus Inc. lowest stock price was $2.71 and its highest was $7.34 in the past 12 months.
What is Agenus Inc.’s market cap?
Agenus Inc.’s market cap is $124.93M.
When is Agenus Inc.’s upcoming earnings report date?
Agenus Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 52 days.
How were Agenus Inc.’s earnings last quarter?
Agenus Inc. released its earnings results on May 11, 2026. The company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.1 by -$1.08.
Is Agenus Inc. overvalued?
According to Wall Street analysts Agenus Inc.’s price is currently Undervalued.
Does Agenus Inc. pay dividends?
Agenus Inc. does not currently pay dividends.
What is Agenus Inc.’s EPS estimate?
Agenus Inc.’s EPS estimate is 0.06.
How many shares outstanding does Agenus Inc. have?
Agenus Inc. has 41,642,430 shares outstanding.
What happened to Agenus Inc.’s price movement after its last earnings report?
Agenus Inc. reported an EPS of $1.02 in its last earnings report, missing expectations of $2.1. Following the earnings report the stock price went down -14.66%.
Which hedge fund is a major shareholder of Agenus Inc.?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (380.17% Upside)
$23.00 (380.17% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.88%
12-Months-Change
Fundamentals
Return on Equity
-23.05%
Trailing 12-Months
Asset Growth
-6.87%
Trailing 12-Months
Company Description
Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
$23.00
▲(380.17% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
1.95% Insiders
10.00% Mutual Funds
3.76% Other Institutional Investors
80.71% Public Companies and
Individual Investors